Knowledge HQ

HDR editing integrates a functional FOXP3 cDNA into CD4+ T cells to create engineered Tregs for IPEX. The study reports targeting efficiency, enrichment, off-target analysis and in vivo suppression. Enriched EngTregs were expanded 7 days in G-Rex® flasks with CD3/CD28 beads, IL-2 and rapamycin.

Base editors are repurposed for targeted knock-in plus simultaneous multiplex knockouts, yielding allogeneic CAR T cells with minimal translocations. Edited CAR T cells were expanded in G-Rex® bioreactors (ScaleReady), and reagents were supported by the ScaleReady G-Rex® Grant Initiative.

Pfizer describes an automated, fully contained cytokine release assay using primary human CD4+ T cells, screening up to 15,000 compounds weekly. Isolated T cells expand 6- to 8-fold in 7 days. G-Rex® 10 open-system flasks (Wilson Wolf) supply the 4-day expansion step of the protocol.

FOXM1 epitopes were immunogenic on HLA-A*02:01, A*24:02 and A*23:01 and endogenously presented. TCR-engineered T cells showed confirmed specificity, reduced tumor growth and prolonged survival in NSCLC models. T cells were cultured with IL2 in G-Rex® 24-well plates (Wilson Wolf) for 4 to 8 days.

Retroviral IL-18, alone or with IL-15, was co-expressed with a GD2 CAR in human NKT cells. IL-18 reprogrammed metabolism and raised cytotoxicity, proliferation and cytokine output over IL-15 alone, outperforming CAR-T cells. NKTs were stimulated and expanded in 24-well G-Rex® plates.

B7-H3 is an actionable CAR target in SCLC and thoracic SMARCA4-deficient tumors, where TGF-beta1 drives resistance. CRISPR knockin of c-JUN with a B7-H3 CAR boosts killing via type I/II cytokines. T cells were activated and expanded in G-Rex® vessels, supporting GMP clinical-scale manufacturing.

Allogeneic mesothelin-targeting CAR-NKT cells were generated from engineered HSPCs with ex vivo differentiation. They killed uterine endometrial carcinoma cells plus CD1d+ TAMs and MDSCs, with no GvHD and minimal CRS. Scalable systems such as G-Rex® are named as a next GMP step.

K562 feeder cells expressing membrane-bound IL-21 preferentially expand Vd1 gamma delta T cells from blood. The cells gain NK activation receptors and kill breast and ovarian tumors, with CAR arming improving efficacy in xenografts. PBMCs were seeded in 24-well G-Rex® plates for expansion.

Primary NK cells from blood, buffy coats and cord blood expanded 30-40x in nine days. An anti-BCMA CAR was delivered as mRNA by LNP, feeder- and virus-free, and the cells killed BCMA+ myeloma lines. Process development scales production in G-Rex® bioreactors to about 800 million cells per dose.

HDR editing at the FOXP3 locus created A2CAR engineered Treg carrying an inducible IL-2 signaling complex. The cells kept a Treg phenotype, stayed minimally cytotoxic, and beat polyclonal EngTreg in a xenogeneic GvHD model. Expansion used G-Rex® gas-permeable culture systems.

A fully non-viral, CRISPR-edited anti-BCMA CAR-T uses TRAC integration and a 1XX CD3z domain. It cleared tumors in myeloma xenografts and outperformed ide-cel and cilta-cel constructs. Manufacturing ran under GMP-compatible conditions with MaxCyte electroporation and G-Rex® expansion.

Chimeric TGF-betaR/IL-2R fusion proteins convert suppressive TGF-beta signals into IL-2 proliferative signals. Engineered CD8+ T cells kept stemness and killed tumors better when paired with a mesothelin TCR. Transduced cells were moved to G-Rex® gas-permeable 24-well vessels to expand.